There are three prolyl hydroxylases (PHD1, 2 and 3) that regulate the hypoxia-inducible factors (HIFs), the master transcriptional regulators that respond to changes in intracellular O 2 tension 1,2 . In high O 2 tension (normoxia) the PHDs hydroxylate two conserved proline residues on HIF-1α, which leads to binding of the von Hippel-Lindau (VHL) tumour suppressor, the recognition component of a ubiquitin-ligase complex, initiating HIF-1α ubiquitylation and degradation 3-6 . However, it is not known whether PHDs and VHL act separately to exert their enzymatic activities on HIF-1α or as a multiprotein complex. Here we show that the tumour suppressor protein LIMD1 (LIM domain-containing protein) acts as a molecular scaffold, simultaneously binding the PHDs and VHL, thereby assembling a PHD-LIMD1-VHL protein complex and creating an enzymatic niche that enables efficient degradation of HIF-1α. Depletion of endogenous LIMD1 increases HIF-1α levels and transcriptional activity in both normoxia and hypoxia. Conversely, LIMD1 expression downregulates HIF-1 transcriptional activity in a manner depending on PHD and 26S proteasome activities. LIMD1 family member proteins Ajuba and WTIP also bind to VHL and PHDs 1 and 3, indicating that these LIM domain-containing proteins represent a previously unrecognized group of hypoxic regulators.
as a specific binding partner of LIMD1 ( Supplementary Fig. S1a ). As LIMD1 shares homology with Ajuba family member proteins Ajuba and WTIP, and within the LIM-domain region with the zyxin LIM domain-containing family members TRIP6, LPP and zyxin, we investigated if these also bound PHD enzymes. We carried out in vivo co-immunoprecipitation assays with Xpress-tagged family member proteins and PHD1, 2 and 3 and discovered differential binding of the PHDs to the family members (Fig. 1a) . LIMD1 bound all three PHDs, whereas the closely related WTIP and Ajuba only bound PHD1 and 3. Out of the more distantly related zyxin family members, the only interaction detected was between TRIP6 and a modified higher-molecularweight form of PHD1 of unknown function (denoted by an arrow in Fig. 1a ). Owing to the homology of the PHD family members and the demonstration that PHD2 is the critical oxygen sensor responsible for the regulation of HIFα (refs 11,12) , we focused our attention on this hydroxylase together with LIMD1 (which bound all three PHDs). In a direct binding assay recombinant LIMD1 bound directly to glutathione S-transferase (GST)-PHD2 in vitro ( Supplementary Fig. S1b-d) .
On the basis of these findings we asked if LIMD1's tumoursuppressive function could, in part, be through formation of a PHD-LIMD1-VHL active complex regulating the HIF-1α degradation pathway, and thus one or more of the many downstream HIF-target genes that have pro-angiogenic, pro-metastatic or other oncogenic functions 13 . To test this possibility, we first immunoprecipitated endogenous PHD2 and found endogenous LIMD1 to co-immunoprecipitate in addition to a higher-molecular-weight form of LIMD1 of unknown modification (most probably representing phosphorylated forms 14 , unpublished data; Fig. 1b ). Immunoprecipitation of endogenous VHL from HEK293 cells resulted in the co-precipitation of elongin B, cullin 2, LIMD1 and PHD2, further supporting the presence of this complex in cells (Fig. 1c) . Furthermore, sucrose-gradient analysis of HEK293 cell extracts demonstrated that LIMD1 was present in the same fractions as PHD2, VHL, elongin B and cullin 2 ( Supplementary Fig. S1e ). These biochemical data supported the existence of a PHD2-LIMD1-VHL complex and also corroborate an earlier in vivo study, where PHD2 purified in a complex with an apparent relative molecular mass above M r 300,000 (300K) (ref. 15) .
The members of the Ajuba family function as protein adapters, simultaneously binding multiple proteins to enable specific regulatory processes 10, 16 . To assess if this function was applicable to HIF-1 regulation we examined if those family members able to bind one or more of the PHDs were also able to bind VHL. In vivo co-immunoprecipitation revealed that both the p19 and p30 isoforms of VHL (refs 17,18) bound specifically to LIMD1, Ajuba and WTIP but not zyxin or LPP (Fig. 1d) . To further validate the endogenous VHL and LIMD1 interaction we also identified this association in HeLa and U2OS cells ( Supplementary Fig. S13f,g ). These data therefore support the concept that LIMD1 is part of a complex that contains the VHL E3 ligase. Of note, we repeatedly observed multiple forms of LIMD1 and VHL in these endogenous co-immunoprecipitation studies (Fig. 1b,c and Supplementary Fig. S1f,g ). These multiple co-precipitated forms of LIMD1 and VHL were specific, as neither control experiments that probed the immunoprecipitating antibodies alone nor experiments carried out in the VHL-deficient RCC4 cell line showed any nonspecific cross-reactivity ( Supplementary Fig. S1i-k) . The multiple forms of VHL match those observed in the sucrose-gradient analysis and have previously been reported 19 . The higher-molecular-weight forms of LIMD1 appear only on concentration of the complex through immunoprecipitation and thus may be specifically modified as a result of complex formation. Such an association between LIMD1 and VHL would predict that they form a functional E3 ligase complex. Consistent with this hypothesis, we detected increased HIF-1α ubiquitylation following LIMD1 overexpression (Fig. 1e) . A PHD2/VHL non-binding mutant ( 186-220 LIM2, see below) was unable to induce ubiquitylation (Fig. 1e) .
We next sought to determine which region of LIMD1 mediates its association with PHD2 and VHL. In vivo co-immunoprecipitation studies with the pre-LIM region of LIMD1 (LIMD1 472-676) and LIM-domain region (LIMD1 1-467; Fig. 1f ) revealed PHD2 bound to the pre-LIM region (Fig. 1g) and VHL bound to the LIM-domain region (Fig. 1h) . These data together with the endogenous co-immunoprecipitation and sucrose-gradient data suggest that LIMD1 may be able to simultaneously bind PHD2 and VHL and therefore may enhance the co-operative function of both proteins by increasing their local concentration, enabling more efficient sequential modification and degradation of HIF-1α. As VHL does not associate directly with PHDs, this hypothesis predicts that the presence of LIMD1 would enable VHL to associate in a complex also containing PHD2 in vivo. In ectopic expression studies, immunoprecipitation of VHL in the absence of transfected plasmids encoding LIMD1 resulted in only very low levels of associated PHD2 (Fig. 1i) ; however, when plasmids encoding LIMD1 were co-transfected this resulted in significantly increased co-precipitation of PHD2 with VHL (Fig. 1i) . Furthermore, immunoprecipitation of transfected plasmids encoding LIMD1 in the presence of PHD2 and VHL resulted in the association of both proteins with LIMD1 and importantly neither impaired the other's ability to bind LIMD1 ( Supplementary Fig. S1l,m) , as would be expected if both proteins interacted with distinct regions of LIMD1 (Fig. 1g,h ) and if LIMD1 acts as an adapter for both proteins. LIMD1 did not bind full-length HIF-1α or its separate sub-domains as determined by in vivo co-immunoprecipitation ( Supplementary Fig. S2a,b) .
We next tested if overexpression of LIMD1 affected HIF-1 transcriptional activity. Ectopic expression of LIMD1 with HIF-1α resulted in significantly reduced hypoxic response element (HRE)-driven luciferase reporter activity (Fig. 2a) . This was specific for LIMD1, as LPP (PHD/VHL non-binder) did not cause any significant repression (Fig. 2b) . Furthermore, HRE transcription in the presence and absence of co-expressed PHD2 indicated that the negative effect of LIMD1 on HIF-1α transcriptional activity was additive with exogenous PHD2 (Fig. 2b) . Western blot analysis of the reporter lysates revealed that LIMD1 caused a decrease in HIF-1α levels ( Supplementary Fig. S2c )
To corroborate the LIMD1 ectopic-expression studies we carried out the converse analysis in cell lines specifically depleted for LIMD1 using lentiviral-driven short hairpin RNA (shRNA) technology and, as a control for potential off-target effects of LIMD1 depletion, in the absence or presence of RNA interference (RNAi)-resistant LIMD1 (rrLIMD1) expressed from the same lentiviral vector 20 ( Fig. 2c) . Depletion of LIMD1 either in normoxia (20% O 2 ) or hypoxia (1% O 2 ) resulted in increased HIF activity, which was restored (or in fact significantly repressed) by concurrent expression of RNAi-resistant LIMD1 (Fig. 2c) . As predicted by the action of LIMD1 on HIF-1α degradation ( Supplementary Fig. S2c ), short interfering RNA (siRNA)-targeted depletion of endogenous LIMD1 increased endogenous HIF-1α protein levels in normoxia (Fig. 2d) and was comparable to that observed following siRNA-targeted depletion of PHD2 (Fig. 2e) .
When LIMD1-depleted cells were exposed to hypoxia we observed a greatly exaggerated increase in HIF-1α protein levels (Fig. 2f) . This result would at first seem paradoxical owing to the inability of VHL to recognize and ubiquitylate unmodified HIF-1α at 1% oxygen. However, it is now clear that in both acute and chronically hypoxic cells PHD2 activity is still present, acting to degrade HIF-1α (refs 21-23) . In addition, VHL can engage HIF-1α in hypoxia and promote VHL-mediated HIF-1α ubiquitylation and degradation 24 . We therefore reasoned that the PHD2-LIMD1-VHL complex may also be functional in hypoxia, potentially as part of the adaptive response to chronic hypoxia, and that depletion of LIMD1 in these conditions would disrupt the complex, leading to further HIF-1α stabilization. To test this possibility, we recapitulated the experiments of ref. 22 with siRNA-targeted depletion of LIMD1 in acute and chronic hypoxia (4-72 h at 1% O 2 ; Fig. 2g ). These experiments revealed that LIMD1 depletion, similarly to PHD2 depletion, caused a significant stabilization of HIF-1α protein in both acute and chronic hypoxia (in addition to normoxia) and inhibited adaptation to chronic hypoxia ( Fig. 2g ; compare HIF-1α expression in control lanes with siRNA depletion of LIMD1 and PHD2 over time in hypoxia). Furthermore, HIF-1α degradation was inhibited following re-oxygenation of hypoxic cells depleted of LIMD1 (Supplementary Fig. S3a ). These results therefore suggest that in hypoxia a significant proportion of cellular HIF-1α continues to undergo LIMD1-dependent degradation; of this only a small proportion is stabilized under hypoxic conditions. The two distinct molecular-weight forms of HIF-1α consistently observed in the above In normoxia, degradation of HIF-1α is a result of hydroxylation and ubiquitylation within the oxygen-dependent degradation domain (ODD) of HIF-1α (refs 6,29). As expression of LIMD1 decreases Anti-HIF-1β
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LIMD1 is a negative regulator of HIF-1α levels and transcription activity. (a) Ectopic co-expression of LIMD1 with HIF-1α represses synthetic pGL3-HRE-luc activity in normoxia and hypoxia when compared with expression of HIF-1α alone. HRE-luc was normalized to a thymidine kinase (TK)-driven Renilla luciferase. Data are mean ± s.d., n = 3 independent experiments, * P < 0.005. (b) Plasmids encoding LIMD1 or LPP were co-transfected plus or minus 1 ng of PHD2. LIMD1 and PHD2 caused HRE repression in an additive manner. LPP did not cause HRE repression and when co-transfected with plasmids encoding PHD2 the level of repression was similar to that for PHD2 expression alone. Data are mean ± s.d., n = 3 independent experiments, * P < 0.005, * * P < 0.05. (c) Lentiviral-driven shRNAs (A and B) were used to deplete endogenous LIMD1 and rescue with an RNAi-resistant LIMD1 in U2OS cells as confirmed by western blot. LIMD1 shRNA A and B represent shRNAs that target different sites within the LIMD1 mRNA 3 untranslated region (3 UTR) and 5 UTR respectively. Rescue experiments were carried out on the shRNA B-depleted background. shRNA-mediated LIMD1 depletion results in enhancement of synthetic pGL3-HRE-luc activity in both normoxia and hypoxia. This is reversed by re-expression of an RNAi-resistant LIMD1. Data are mean ± s.d., n = 3 independent experiments, * P < 0.005, * * P < 0.05. (d,e) siRNA (80 nM)-mediated depletion of LIMD1 in U2OS (d) and HEK293 (e) cells causes an increase in HIF-1α protein levels in normoxia comparable to that caused by siRNA depletion of PHD2. SCR, scrambled. (f) siRNA-mediated depletion of LIMD1 (80 nM) in U2OS cells also caused an increase in HIF-1α protein levels in hypoxia and had no effect on HIF-1β protein levels.
(g) siRNA-mediated depletion of LIMD1, PHD2 or both caused an increase in HIF-1α protein levels in normoxia and up to 72 h hypoxia.
HIF-1α levels ( Supplementary Fig. S2c ), we asked if increased LIMD1 expression would have a specific negative effect on stability of the ODD domain of HIF-1α alone. Expression of LIMD1 resulted in reduced levels of ODD, but not of the amino (amino acids 30-389)-or carboxy (amino acids 630-826)-terminal domains (Fig. 3a) . In contrast, TRIP6, which does not bind PHD2 (Fig. 1a) , did not induce ODD degradation (Fig. 3a,c) . We next used the shRNA lentiviral-infected cell lines to test the converse prediction with respect to ODD protein levels and LIMD1 expression. Depletion of LIMD1 resulted in an increase in ODD expression (arrowhead) that is reduced with re-expression of rrLIMD1 (Fig. 3b) . Family members Ajuba and WTIP, which bind both PHD and VHL, were also able to induce ODD degradation (Fig. 3c) .
The dependence on hydroxylase and proteasomal activities for LIMD1-mediated regulation of ODD levels was examined next. In the presence of DMOG (a competitive inhibitor of 2-oxoglutarate (2-OG)-dependent oxygenases) or MG132 (a 26S proteasome inhibitor), LIMD1, Ajuba, WTIP and PHD2 were unable to induce a reduction in ODD levels, confirming a requirement for both enzymatic activities (Fig. 3d,e) .
A further prediction of our proposed PHD2-LIMD1-VHL complex would be that PHD2/VHL-non-binding LIMD1 mutants would be unable to induce degradation of ODD or HIF, deregulate HIF activity in reporter assays or may even act in a dominant inhibitory manner. To create non-binding mutants in the context of full-length LIMD1 the internal binding sites within LIMD1 were mapped for PHD2 ( 186-260) and VHL ( LIM2; Supplementary Fig. S4a ,b, respectively).
As predicted, the double PHD2/VHL non-binding mutant ( 186-260-LIM2) did not induce ODD degradation when overexpressed in the presence of endogenous LIMD1 (Fig. 3f) , indicating the requirement of associated PHD hydroxylase and/or VHL ubiquitin-ligase activities for LIMD1 to regulate this pathway. In an endogenous LIMD1-depleted background the capability of rrLIMD1 (expressed at levels comparable to endogenous LIMD1) to degrade ODD was lost on rescue with rr 186-260-LIM2 or rr LIM2 mutants (Fig. 3g) . In contrast, rescue with rr 186-260 alone was able to influence ODD degradation. These results suggest that the VHL association with LIMD1 is pivotal for LIMD1-induced HIF degradation, and could also suggest a LIMD1-independent PHD modification of HIF-1α. These ODD results were mirrored when the same cell lines were analysed for HRE activity in normoxia (Fig. 3h) . Interestingly, when the same assay was carried out under hypoxia the rr LIM2 mutants resulted in a dominant negative effect on HRE-luc transcription (Fig. 3 compare h and i ). This indicated (1) that in hypoxia engaging VHL is critical or (2) that the ability to bind and sequester PHD2 away from VHL may further stabilize The same stably expressing lentiviral shRNA B cell lines were transfected with synthetic pGL3-HRE-luc and TK-Renilla (for normalization). LIMD1 depletion caused an increase in HRE transcriptional activation, which was repressed with re-expression of an rrLIMD1. Rescue with rrLIMD1 unable to bind PHD2 and VHL ( 186-260 LIM2) increased in HRE transcriptional activation to the same extent as LIMD1 depletion. Data are mean ± s.e.m., n = 3 independent experiments, * P < 0.005, * * P < 0.05. (i) Reporter analysis as in h was also carried out in hypoxia. (j) U2OS cells were transiently transfected with GFP vector only, GFP-PHD2, GFP-FIH, GFP-LIMD1 and GFP-zyxin. At 44 h following transfection, cells were exposed to 1% O 2 for 4 h. Cells were then fixed and immunostained for endogenous HIF-1α and nuclear stained using 4,6-diamidino-2-phenylindole (DAPI). Expression of LIMD1 reduced HIF-1α expression levels and inhibited its nuclear accumulation; this was comparable in effect to GFP-PHD2. GFP-VO and GFP-FIH do not affect HIF-1α stability or localization. Scale bars, 20 µm. extra HIF-1α that is being hydroxylated and degraded through LIMD1-uncomplexed PHD2/VHL. Using a previously described immunofluorescence assay to detect HIF-1α (ref. 30) , we examined the effect of ectopic LIMD1 on endogenous HIF-1α protein levels in vivo. Expression of green fluorescent protein (GFP)-LIMD1 induced a reduction in HIF-1α expression and inhibited nuclear accumulation (Fig. 3j) , similar to expression of GFP-PHD2 (Fig. 3j) . As further controls, expression of GFP only and factor inhibiting HIF (FIH) (ref. 31) had no effect on HIF-1α expression level or localization (Fig. 3j) . We believe that the overexpression of LIMD1 enhances formation of the complex, concentrating and recruiting any residually active PHD2 and VHL to HIF, thus facilitating its degradation. Family member zyxin, which does not bind VHL or PHD2, was used as a negative control (Fig. 3j,  bottom panel) , showing that the ability of a protein to engage PHD2 and VHL is critical for HIF-1α degradation.
To further explore the physiological consequences of LIMD1 loss we examined the effect of depletion of endogenous LIMD1 on endogenous HIF-target genes (Fig. 4) . siRNA-mediated LIMD1 depletion in U2OS cells resulted in a significant increase in both BNIP3 and VEGF messenger RNA levels in hypoxia (Fig. 4a-d) . These responses were further validated in HEK293 cells for an extra set of HIF-responsive genes and with the inclusion of siRNA-targeted PHD2 depletion as a further control (Fig. 4e) . Of note, there were clear gene-specific responses to LIMD1 and PHD2 depletion in both normoxia and hypoxia (Fig. 4e) , and also differences in responses of genes between U2OS and HEK293 cell lines (Fig. 4a,b , compare BNIP3 in normoxia on LIMD1 depletion). One possible explanation for this could be the phosphorylation status (Supplementary Fig. S3b ) and thus possible transcriptional activity of HIF-1 between these cell lines and also activity towards specific responsive genes discussed above. Furthermore, a similar observation was recently shown in ref. 32 , with the same unresponsiveness of endogenous HIF-1-responsive genes on increase in HIF-1α level through depletion of MCM3 in normoxia, but increased responsiveness in hypoxia (see Fig. 2k in ref. 32 ). Taken together, these results indicate that reduction of endogenous LIMD1 is sufficient to increase HIF-1α levels, HIF transcriptional activity and expression of endogenous HIF target genes.
In summary, we have shown that the Ajuba LIM proteins, particularly LIMD1, act to facilitate assembly of a PHD2-LIMD1-VHL protein complex that bridges the activities of PHD2 and VHL to enable efficient modification and degradation of HIF-1α. These findings suggest a new level in the regulation of HIF-1α whereby hydroxylation and ubiquitylation are intimately associated enzymatic activities in a complex, allowing for efficient and rapid post-translational modification of HIF and its subsequent rapid degradation. Such a model allows for further regulation of HIF-1α through regulation of complex association/formation (Fig. 5) .
HIF modification is a critical regulatory step in the cellular response to low O 2 . Such a step requires tight, adaptive and diverse regulation to enable multiple signalling pathways to impinge on the hypoxic response with further levels of regulation. LIMD1, Ajuba and WTIP are unique among a growing group of PHD/HIF-1α binding proteins (Siah1/2, FKBP38 and MCM family [32] [33] [34] [35] ) as they are the only regulators to simultaneously bind PHDs and VHL. Furthermore, given differential binding to the three PHDs, the operation of such complexes could potentially explain the fundamental paradox of how the simple biochemical/kinetic properties of the hydroxylase-ubiquitin ligase couple may be adapted to provide the flexibility necessary for physiological oxygen homeostasis. hypoxia we propose that LIMD1 still engages an active pool of PHD2 together with VHL to enable a degree of HIF-1α degradation in hypoxia. However, this is not sufficient to prevent build-up and the classic HIF-driven transcriptional response. Furthermore, this complex may be critical for adaptation to hypoxia. (e) In normoxia with LIMD1 depletion we propose that this results in a disengagement of PHD2 from VHL, resulting in reduced efficiency of HIF-1α modification and degradation. Under such conditions there is a significant increase of HIF-1α levels, of which a small proportion may become phosporylated and thus transcriptionally active. (f) In hypoxic conditions with LIMD1 depletion (compare d and f) we see a greatly exaggerated increase in HIF-1α, which we believe indicates a loss of the LIMD1-dependent HIF-1α degradation that occurs under hypoxic conditions. Our model does not rule out the existence of LIMD1-independent PHD/VHL-driven HIF-1α degradation pathways, but proposes that these are significantly less efficient than the LIMD1-dependent one.
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METHODS
Cell culture and transfections. Human cell lines (U2OS, HeLa, HEK293, HEK293T) were cultured in DMEM (PAA Laboratories), supplemented with 10% (v/v) fetal calf serum (Sigma), 50 U ml −1 penicillin and 50 g ml −1 streptomycin (Sigma). Hypoxic treatment at 1% O 2 was achieved using a ProOx 110 (BioSpherix) controller and chamber. Proteasomal inhibition was with 10 µM MG-132 (Enzo) for 4 h. 2-OG dioxygenase inhibition was achieved using 1 mM DMOG for 4 h. For transfected co-immunoprecipitation assays, siRNA and qRT-PCR, 2×10 5 U2OS or 4×10 5 HEK293T cells were plated into six-well plates. For transient transfection and reporter assays, 5×10 4 U2OS or 8×10 4 U2OS shRNA lines were plated into 12-well plates. U2OS cells were transfected using Genejuice (Merck Biosciences) or TransIT LT1 (Mirus Bio) and HEK293T cells were transfected using TransIT 293. siRNA was transfected using DharmaFECT Duo or Dharma FECT 1 (Dharmacon) transfection reagents. Transfections were as per manufacturer's instructions.
siRNA and shRNA stable line production. The siRNA sequence (Sigma Mission siRNA) against LIMD1 was as follows: 5 -GCAAGGAGGUCUUCCAAGA-3 (assay code SASI_Hs01_00095038).
The shRNA sequences against LIMD1 were as follows. shRNA A: hLIMD1 shRNA 3 UTR, 5 -GCAGAATGGCTGCAAATTTAA-3 . shRNA B: hLIMD1 shRNA 5 UTR, 5 -GTCTGCAGCATGGATAAGTA-3 .
U2OS stable cell lines were generated using the lentiviral shRNA-driven LIMD1 knockdown and rescue system, as previously described 36 . The gene delivery and production system was as previously described 37 .
Plasmids. Generation of pcDNA4/HisMax (Invitrogen) Xpress-LIMD1 and LIMD1 deletion mutants and pcDNA3.1 PHD1, 2, 3 have previously been described 38, 39 . pcDNA3.1 (Invitrogen) HIF-1α, FIH, VHL, HA-enhanced GFP (eGFP)-ODD, N-terminal HIF-1α, C-terminal HIF-1α and pGL3-HRE plasmids were kindly donated by Thilo Hagen, National University of Singapore. pcDNA3.1 mLIMD1 and mLIMD1 deletion mutants, and pFLRu Scr-GFP, hLIMD1 shRNA-GFP, hLIMD1 shRNA rrhLIMD1-FH and hLIMD1 shRNA rrhLIMD1 LIM2-FH were donated by Y. Feng and G. Longmore, Washington University 20, 36 . pGEX4T-1-LIMD1 and pEGFP-LIMD1 were generated as follows. LIMD1 complementary DNA was excised from pcDNA4/HisMax-LIMD1 using EcoRI and SalI restriction endonucleases and ligated into similarly cut pGEX4T-1 (Amersham) and pEGFP C1 + 1 vector (donated by S. Dawson, University of Nottingham) respectively. Xpress-tagged PHD1, 2 and 3 were generated by PCR amplification of cDNA from pcDNA3.1-PHD1,2 and 3, incorporating flanking BamHI and EcoRI sites (for PHD3 BglII and EcoRI ) and cloned into the pcDNA4/HisMax vector (Invitrogen). pEGFP-PHD1, 2 and 3 were generated by restriction digest from pcDNA4/HisMax into the pEGFP vector. Xpress-tagged LIMD1 conserved-region deletion mutants 112-123, 140-166, 186-260, 239-260, 298-315, 342-369, 429-464, LIM2 (residues 537-591) and double mutant 186-260-LIM2 were generated from pcDNA4/HisMax LIMD1 through the QuikChange site-directed mutagenesis method (Stratagene). Using the same method, pFLRu-hLIMD1 shRNA + rrhLIMD1 186-260-FH and LIM2-FHwere generated from template pFLRu-hLIMD1 shRNA + rrLIMD1 and subsequently pFLRu-hLIMD1 shRNA + rrhLIMD1 186-260 LIM2-FH was generated from pFLRu-hLIMD1 shRNA + rrhLIMD1 186-260-FH.
Forward primer sequences for the mutagenesis of Xpress-tagged LIMD1 conserved-region deletion mutants were as follows: 112-123, 5 -CTTGCTGCCT-CGACACAGCCCCCGTAC-3 ; 140-166, 5 -CCATACCTGCATCCCTGTGAGG-ATC-3 ;
186-260, 5 -GGAGACTATTATGACAACCTCTCCTTGGGCCTTTG-GTCCACTGCCTCCTC-3 ; 239-260, 5 -CTGAGCTCCAGCAGGGGCCTTTG-GTCC-3 ; 298-315, 5 -AGGACCCCTTCTGTGTCGGGGCTGGGGGGTG-3 ; 342-369, 5 -CAGGATGGGCCCCCGAAGCCTGGCTGC-3 ; 429-464, 5 -TCC-CCTAGGGTAAGGAAGGCTGATTAC-3 ; LIM2 (residues 537-591), 5 -CTGGT-TTCCAGCAGTCGGCTGACAGGGTGCTGGCCCCCAAGTGTGCAGCC-3 . Reverse primers were exact reverse complements of the forward primers.
Yeast two-hybrid screen. LIMD1 364-676cDNA was released from pcDNA4 /HisMax LIMD1 364-676 vector and ligated into the similarly cut pAS2.1 bait vector. The resulting plasmid (pAS2.1-LIMD1-364-676) was pretransformed into the Saccharomyces cerevisiae PJ69-4a (MAT a trp1-90 leu2-3,112 ura3-52 his3-200 gal4 gal80 LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ ) (14) reporter strain by using a modified lithium acetate protocol (see Yeast Protocols Handbook, BD Biosciences Clontech). Subsequently, this strain was cotransformed with the BC3 cDNA library (produced by using the Stratagene HybriZAP cDNA library kit) in the GAL4 DNA activation domain (GAL4AD) fusion 'prey' vector. Selection for positive colonies and cDNA clone isolation were as previously described 40 .
Sucrose-gradient fractionation. HEK293 were lysed in 25 mM Tris-HCl at pH 7.4, 150 mM KCl, 0.5% NP-40, 2 mM EDTA, 1 mM NaF, 0.5 mM dithiothreitol supplemented with 'Complete' protease inhibitors (Roche) and PhosSTOP phosphatase inhibitors (Roche) 41 . The cell lysate was rotated at 4 • C for 30 min, centrifuged at 13,000 r.p.m. for 10 min, and the cleared lysate applied to a 10-35% discontinuous sucrose gradient in polyallomer tubes. The gradient was centrifuged at 30,000 r.p.m. for 16.5 h (SW41Ti rotor, Optima LE-80 K ultracentrifuge), and 500 µl fractions were collected from the top of the gradient (fraction number 1) downwards to the bottom of the gradient (fraction number 17).
In vitro binding assays. pGEX4T-PHD2 and pGEX6P-LIMD1 were transformed into BL21 (DE3)-pLysS chemically competent bacteria. Cultures were grown for 3 h before induction with IPTG followed by a further 4 h growth at 37 • C. Bacteria were pelleted, freeze-thawed and lysed by sonication. Recombinant proteins were purified onto glutathione Sepharose 4B (GE Healthcare 17-0756-01). Recombinant LIMD1 was cleaved from the Sepharose using PreScission protease (GE Healthcare 270843) in binding buffer (50 mM Tris-HCl at pH 7.0, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol). Equal amounts of the cleaved recombinant LIMD1 were incubated with either purified GST vector only or GST-PHD2 for 6 h at 4 • C and washed three times with binding buffer. Ubiquitylation assay. This assay was essentially carried out as described in ref. 32 . Briefly: cells were transfected with expression vectors encoding V5-HIF-1α, Flag-ubiquitin, EV or Xpress-LIMD1. Cells were lysed, mixed and incubated for 1 h at 37 • C. Lysates were then immunoprecipitated with V5 antibody (AbD Serotec) followed by immunoblot with antibodies to HIF-1α (BD Transduction Laboratories, 1:500 dilution) or Flag (Sigma Aldrich, 1:1,000).
Antibodies.
A list of all primary and secondary antibodies and dilutions used can be found in Supplementary Tables S1 and S2 respectively.
Reporter assays. Cells were co-transfected in triplicate with pGL3-(6x)HRE-firefly luciferase and TK-Renilla luciferase reporters. 24 h post-transfection cells were lysed in 1× passive lysis buffer (Promega) and freeze-thawed. Luciferase activity was assayed using the dual luciferase reporter assay system (Promega) and TopCount scintillation and luminescence counter (Perkin Elmer).
Phosphatase assay. Cells were exposed to 1% O 2 for 16 h before lysis by scraping in RIPA buffer supplemented with 'Complete' protease and phosphatase inhibitors and 10 µM MG-132. Cleared lysates were added to 2.5 µgHIF-1α or control antibody conjugated to immunoprecipitation matrix. Immunoprecipitation of HIF-1α was carried out for 4 h at 4 • C with rotation, followed by extensive washing with unsupplemented RIPA buffer. Dephosphorylation was carried out in 50 µlreaction volumes using 400 units of λ protein phosphatase (NEB no P0753S) at 30 • C for 60 min along with a control reaction that omitted the enzyme. The reaction was stopped by addition of 5 × SDS-PAGE sample buffer. 
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